Connecticut is currently home to 1228 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Cardiovascular Disease Risk in Women With Endometriosis
NCT03746535
Recruiting
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
01/23/2025
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Endometriosis
Register for Updates
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
NCT05473910
Recruiting
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Yale, New Haven, Connecticut
Conditions: AML, Myelodysplastic Syndromes, ALL, Adult
Register for Updates
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine
NCT05053321
Recruiting
This will be an Investigator-initiated pilot study in which participants will be assessed with various scales to measure demoralization, anxiety, depression, and subjective incompetence at baseline and every two weeks after treatment with Valbenazine for a total of 6 weeks. Improvement in TD will be assessed as well and correlated with reduction in demoralization.
Gender:
ALL
Ages:
Between 26 years and 84 years
Trial Updated:
01/22/2025
Locations: Yale Church Street Research Unit., New Haven, Connecticut
Conditions: Tardive Dyskinesia
Register for Updates
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
NCT04748601
Recruiting
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
01/22/2025
Locations: Upsher-Smith Clinical Trial Site #1, Stamford, Connecticut
Conditions: Migraine Disorders
Register for Updates
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
NCT03328078
Recruiting
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies. This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut
Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Register for Updates
Integrative Training Program for Pediatric Sickle Cell Pain
NCT06691867
Recruiting
This research aims to answer the question: does a group training program specifically for teens with chronic sickle cell disease (SCD) pain that teaches skills to strengthen the mind and body help improve everyday functioning and reduce pain symptoms? The program will be tailored to address challenges related to frequent or chronic sickle cell pain and may improve participants' physical and emotional health. The program, called I-STRONG for SCD (Integrative Strong Body and Mind Training for Si... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
01/21/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Sickle Cell Disease
Register for Updates
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
NCT06413433
Recruiting
ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/21/2025
Locations: Clinical Research Site, Cromwell, Connecticut
Conditions: Binge-Eating Disorder
Register for Updates
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
NCT06058702
Recruiting
Cannabis is widely used worldwide and is associated with negative outcomes including cannabis use disorder (CanUD), psychosis, and cognitive impairment amongst others. Given the legalization of "recreational" and "medical" cannabis globally, the increasing availability of cannabis, the higher potency of cannabis, the availability of highly potent cannabinoid products, the commercialization of cannabis, and the rising rates of cannabis use, it is critical to understand how genetic factors influen... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
01/21/2025
Locations: West Haven Veterans Affairs Medical Center, West Haven, Connecticut
Conditions: Schizophrenia, Cannabis Use Disorder
Register for Updates
SV2A Density Cannabis Use Disorder
NCT05472818
Recruiting
The main purpose of this study is to determine whether hippocampal synaptic vesicle density estimated by hippocampal \[11C\]APP-311/\[11C\]UCB-J binding in individuals diagnosed with cannabis use disorder (CUDs) improves with at least 4 weeks of confirmed abstinence from cannabis, in comparison to healthy controls (HCs). Furthermore, any change in synaptic vesicle density will be placed in functional context by measuring verbal memory, which is sensitive to hippocampal function, before and after... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/21/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Cannabis Use Disorder, Healthy
Register for Updates
Building an Equitable and Accessible System of Eating Disorder Care for VA, DoD, and Underrepresented Americans
NCT05304104
Recruiting
When untreated, eating disorders present with tremendous burdens to affected active duty Service members and Veterans and their families, and are very costly to the DoD and VA healthcare system. A comparative effectiveness study with state-of-the-art virtual treatment for BN and BED specifically adapted for testing with the Veteran population and other underrepresented eating disorder populations will lead to major improvements in clinical outcomes. The treatment will be integrated with VA's new... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Binge-Eating Disorder, Bulimia Nervosa, Veterans Health, Cognitive Behavioral Therapy
Register for Updates
Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs
NCT02493478
Recruiting
Advanced airway interventions are common high risk, high stakes events for children in intensive care units (ICU) and emergency departments (ED), with risk for life and health threatening consequences.
Gender:
ALL
Ages:
All
Trial Updated:
01/21/2025
Locations: Yale New Haven Children's Hospital, New Haven, Connecticut
Conditions: Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Register for Updates